Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 1;30(1):33-39.
doi: 10.1097/MOO.0000000000000776.

Emerging concepts in sinonasal tumor research

Affiliations
Review

Emerging concepts in sinonasal tumor research

Diana C Lopez et al. Curr Opin Otolaryngol Head Neck Surg. .

Abstract

Purpose of review: Sinonasal malignancies are rare and understudied, often diagnosed at late stages, and may behave aggressively. This review explores investigative diagnostic, therapeutic, and scientific advances specific to sinonasal undifferentiated carcinoma (SNUC), intestinal-type adenocarcinoma (ITAC), and olfactory neuroblastoma (ONB).

Recent findings: A number of studies have recently contributed more robust knowledge of the genetic and molecular landscapes of SNUC, ITAC, and ONB. These analyses have identified SMARCB1 and IDH2 mutations in SNUC, potentially allowing for the tumor's subdivision. Recent studies have also defined a role for induction chemotherapy in SNUC. Somatic mutations for ITAC have been identified and may be potentially targetable with FDA approved therapies. Studies defining the tumor microenvironment for ITAC and ONB have introduced the possibility of immune checkpoint inhibition for these tumor types.

Summary: Studies reviewed here detail promising results of the most current and novel characterization of SNUC, ITAC, and ONB genetic and molecular landscapes, which have informed ongoing therapeutic discovery. With continued multi-institutional efforts, the field of sinonasal tumor research will achieve higher disease control and improved treatment outcomes for patients afflicted with these rare cancers.

PubMed Disclaimer

References

    1. Hermsen MA, Riobello C, García-Marín R, et al. Translational genomics of sinonasal cancers. Semin Cancer Biol 2020;61:101–9. - PubMed
    1. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012;34(6):877–85. - PubMed
    1. Bossi P, Hermsen M, Lechner M, Franchi A. Precision medicine in rare tumors and the need for multicenter trials and international collaboratives: Sinonasal cancer as paradigm. Oral Oncol 2020;109:104737. - PubMed
    1. Llorente JL, López F, Suárez C, Hermsen MA. Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol 2014;11(8):460–72. - PubMed
    1. Costales M, López-Hernández A, García-Inclán C, et al. Gene Methylation Profiling in Sinonasal Adenocarcinoma and Squamous Cell Carcinoma. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg 2016;155(5):808–15. - PubMed

MeSH terms

Substances